Peripartum cardiomyopathy: Current therapeutic perspectives

  title={Peripartum cardiomyopathy: Current therapeutic perspectives},
  author={Sabrina D Phillips and Carole A. Warnes},
  journal={Current Treatment Options in Cardiovascular Medicine},
  • S. Phillips, C. Warnes
  • Published 1 December 2004
  • Medicine
  • Current Treatment Options in Cardiovascular Medicine
Peripartum cardiomyopathy is a rare condition of unclear etiology that accounts for an important percentage of pregnancy-related deaths. Deaths from peripartum cardiomyopathy can be attributed to profound left ventricular failure, thromboembolic events, or arrhythmia. Prompt recognition of the condition, initiation of appropriate medical management, collaboration with perinatology for delivery management, referral to cardiac transplant centers when necessary, and counseling regarding future… 
Peripartum Cardiomyopathy: Review of the Literature
A comprehensive updated review of PPCM is provided covering etiopathogeneses, clinical presentation and diagnosis, as well as pharmacological, perioperative and intensive care management and prognosis, while stressing areas that require further research.
Peripartum cardiomyopathy
Mortality rates in peripartum cardiomyopathy have decreased, and this is most likely related to advances over the past 5 yrs in medical therapy for heart failure.
Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments
The medical management of PPCM is similar to other forms of non-ischaemic dilated cardiomyopathy, but with the management tailored to choose safe drugs in pregnancy and lactation to minimise maternal and fetal morbidity.
Peripartum Cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a rare form of unexplained cardiac failure of unknown origin, unique to the pregnant woman with highly variable outcome associated with high morbidity and
Peripartum Cardiomyopathy: A Case Series
Peripartum cardiomyopathy (PPCM) is a life threatening entity of peripartum period characterized by left ventricular systolic dysfunction and heart failure in absence of any known cardiac disease.
Peripartum Cardiomyopathy: An Update
The aim of this review is to highlight peripartum cardiomyopathy pathophysiology, emerging investigatios modalities, and updated management protocol.
Severe preeclampsia, pulmonary edema, and peripartum cardiomyopathy in a primigravida patient.
The presentation and anesthetic management of a parturient who was admitted with a diagnosis of severe preeclampsia in whom pulmonary edema and heart failure developed, necessitating emergency cesarean delivery under general anesthesia is described.
Current knowledge and recent development on management of peripartum cardiomyopathy
Current management of peripartum cardiomyopathy is highlighted as targeted therapy has far been disappointing, and targeted therapies such as pharmacological prolactin blockade are under evaluation.
Recovery from peripartum cardiomyopathy in a Japanese woman after administration of bromocriptine as a new treatment option.
A Japanese woman with acute PPCM treated with bromocriptine is presented and it is presented that following treatment, the serum prolactin levels dropped swiftly, and heart failure symptoms decreased, accompanied by a decrease in the BNP level.
Case Report: Peripartum Cardiomyopathy with Thromboembolic Episodes
A type of dilated cardiomyopathy presenting as heart failure due to left ventricular systolic dysfunction in late 3 trimester of pregnancy or within 5 months post delivery when no other cause of heart failure is detectable.


Myocarditis and long-term survival in peripartum cardiomyopathy.
In patients with PPCM, long-term survival is better than has been historically reported, the prevalence of myocarditis is high, and decreased left ventricular stroke work index is associated with worse clinical outcomes.
Peripartum Cardiomyopathy Due to Myocarditis
In the evaluation of patients with peripartum cardiomyopathy it is necessary to exclude or identify myocarditis immediately because of the important therapeutic implications and has included endomyocardial biopsy in the diagnostic workup of .
Intravenous immune globulin in the therapy of peripartum cardiomyopathy.
Natural Course of Peripartum Cardiomyopathy
In those patients in whom cardiomegaly persisted, the prognosis was poor, and subsequent pregnancies were likely to lead to permanent deterioration, but in those in whom the heart size returned to normal the prog outlook was excellent.
Autoimmune mechanisms as the basis for human peripartum cardiomyopathy
Findings for the first time suggest that such abnormalities may in concert lead to the initiation and perpetuation of an autoimmune process, which leads to cardiac failure and disease.
Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function.
Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review.
Peripartum cardiomyopathy is a rare lethal disease about which little is known and diagnosis is confined to a narrow period and requires echocardiographic evidence of left ventricular systolic dysfunction.
Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection.
Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy.
Subsequent pregnancy in women with a history of peripartum cardiomyopathy is associated with a significant decrease in left ventricular function and can result in clinical deterioration and even death.